Roivant Sciences' (ROIV) subsidiary Genevant Sciences and Arbutus Biopharma (ABUS) said Monday they have filed five international lawsuits seeking to enforce patents protecting their lipid nanoparticle technology against infringement by Moderna and certain affiliates.
The enforcement actions target alleged infringing activities in 30 countries, the two companies said. They are seeking monetary relief and injunctions against Spikevax and, where applicable, additional Moderna products that allegedly use the same technology, including mRESVIA.
Lawsuits were filed in courts in Canada, Japan and Switzerland, while two were filed in the European Union's Unified Patent Court.
The enforcement actions expand on the two companies' ongoing enforcement proceeding in the US District Court for the District of Delaware, seeking fair compensation for Moderna's alleged infringement of six US patents in the manufacture and sale of Spikevax. A jury trial is currently scheduled for September, they said.
Moderna did not immediately respond to a request for comment from MT Newswires.
Price: 10.44, Change: -0.30, Percent Change: -2.79
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。